On January 20, 2017, Abattis Bioceuticals Corp. (OTCPK:ATTB.F) closed the transaction. The company issued 433,000 shares for the gross proceeds of CAD 50011.5. Each warrant entitles the holder to acquire one common share at a price of CAD 0.1875 for a period expiring on July 1, 2018.